Early vascular responses to everolimus-eluting cobalt-chromium stent in the culprit lesions of st-elevation myocardial infarction: results from a multicenter prospective optical coherence tomography study (MECHANISM-AMI 2-week follow-up study).
Aged
Cardiovascular Agents
/ administration & dosage
Chromium
/ administration & dosage
Cobalt
/ administration & dosage
Coronary Angiography
/ methods
Coronary Vessels
/ diagnostic imaging
Drug-Eluting Stents
/ adverse effects
Everolimus
/ administration & dosage
Female
Follow-Up Studies
Humans
Male
Middle Aged
Percutaneous Coronary Intervention
/ adverse effects
Prospective Studies
ST Elevation Myocardial Infarction
/ surgery
Tomography, Optical Coherence
/ methods
Treatment Outcome
Drug-eluting stent
Myocardial infarction
Optical coherence tomography
Thrombus
Journal
Cardiovascular intervention and therapeutics
ISSN: 1868-4297
Titre abrégé: Cardiovasc Interv Ther
Pays: Japan
ID NLM: 101522043
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
20
10
2017
accepted:
27
12
2017
pubmed:
11
1
2018
medline:
18
6
2019
entrez:
11
1
2018
Statut:
ppublish
Résumé
The use of cobalt-chromium everolimus-eluting stents (CoCr-EES) for ST-segment elevation myocardial infarction (STEMI) reduces the incidence of stent thrombosis compared with bare metal stents, and a substantial difference is apparent in the initial 2 weeks. However, vascular behavior during this early period remains unclear. This was a prospective study (MECHANISM-AMI-2W) to investigate early vascular responses in STEMI patients immediately after CoCr-EES implantation and at 2-week follow-up using frequency domain-optical coherence tomography (FD-OCT). The study enrolled 52 patients (age 63.7 ± 11.7 years, male 85.0%), of whom 44 patients were available for complete serial FD-OCT analyses. Both % uncovered struts and % malapposed struts were improved at 2-week follow-up (63 ± 20 vs. 21 ± 14%, p < 0.0001 and 7.3 ± 9.0 vs. 4.7 ± 5.9%, p = 0.005, respectively). Thrombus was decreased, with significant changes in longitudinal length to stent (28.8 ± 27.7 vs. 18.1 ± 20.2%, p = 0.0001) and maximal area (0.93 ± 0.84 vs. 0.65 ± 0.63 mm
Identifiants
pubmed: 29318464
doi: 10.1007/s12928-017-0507-4
pii: 10.1007/s12928-017-0507-4
pmc: PMC6329740
doi:
Substances chimiques
Cardiovascular Agents
0
Chromium
0R0008Q3JB
Cobalt
3G0H8C9362
Everolimus
9HW64Q8G6G
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
14-24Références
Eur Heart J. 2007 Apr;28(8):961-7
pubmed: 17135281
Circulation. 2011 Jan 25;123(3):274-81
pubmed: 21220730
Circulation. 2012 Oct 16;126(16):2020-35
pubmed: 22923432
J Am Coll Cardiol. 2013 Aug 6;62(6):496-504
pubmed: 23747778
Circ J. 2012;76(12):2822-31
pubmed: 22971949
Lancet. 2010 Jan 23;375(9711):283-93
pubmed: 20079528
N Engl J Med. 2014 Dec 4;371(23):2155-66
pubmed: 25399658
Circulation. 2005 Mar 29;111(12):1551-5
pubmed: 15781733
Eur Heart J Cardiovasc Imaging. 2015 Apr;16(4):433-40
pubmed: 25428947
Circ J. 2014;78(10):2408-14
pubmed: 25099476
Lancet. 2009 Feb 28;373(9665):723-31
pubmed: 19249633
EuroIntervention. 2016 Nov 20;12(10):1239-1245
pubmed: 26606735
EuroIntervention. 2016 Oct 20;12(9):1090-1101
pubmed: 27597270
Circulation. 2015 Sep 15;132(11):1020-9
pubmed: 26162917
Circulation. 2008 Sep 9;118(11):1138-45
pubmed: 18725485
Eur Heart J. 2016 Apr 14;37(15):1208-16
pubmed: 26757787
Circulation. 2011 Apr 5;123(13):1400-9
pubmed: 21422389
Lancet. 2012 Oct 27;380(9852):1482-90
pubmed: 22951305
EuroIntervention. 2014 Dec;10(8):916-23
pubmed: 24974806
Circ J. 2016 Sep 23;80(10):2063-72
pubmed: 27616595
Eur Heart J. 2012 Apr;33(8):977-87
pubmed: 22362513
Int Heart J. 2015;56(4):389-94
pubmed: 26118594
Eur Heart J Cardiovasc Imaging. 2015 May;16(5):513-20
pubmed: 25428946
BMJ. 2013 Nov 08;347:f6625
pubmed: 24212107
JACC Cardiovasc Interv. 2015 Aug 17;8(9):1248-1260
pubmed: 26292590
JAMA. 2012 Aug 22;308(8):777-87
pubmed: 22910755
Eur Heart J Cardiovasc Imaging. 2014 Jul;15(7):800-9
pubmed: 24497520